Introduction
As the incidence of prostate cancer continues to rise, due in part to the demographic shift to longevity, there has been a parallel rise in the associated mortality. Currently, prostate cancer accounts for 41% of all male cancers diagnosed in the USA.
The annual incidence has doubled over the past 5 y and it is now anticipated that one in every six American males will be diagnosed with cancer of the prostate during his lifetime. 1 Moreover, in 1996 it was predicted that over 300 000 new cases of prostate cancer would be diagnosed in the USA with a resulting mortality of about 44 000. The average lifespan of patients dying of prostate cancer is reduced by 9.2 y. 2 From these ®gures, it is clear that prostate cancer presents an increasing clinical dilemma, 3 especially as there is currently no single accurate predictor of outcome once this malignancy has been detected. 4 Therefore, new insights into the biological mechanisms which underlie the development and progression of this carcinoma are urgently required.
The presence of a persistently elevated or rising serum PSA post radical prostatectomy raises unresolved clinical management issues 5 and the role of pelvic irradiation in these cases is unproven. 6 The main dif®culty encountered, is the ability of current staging modalities to accurately assess the extent of recurrent disease and it is in this context that prostate-speci®c membrane antigen (PSM/FOLH1) initially showed its clinical potential.
7±10
Interestingly, it has subsequently been argued that polymerase chain reaction (PCR) based diagnostic detection of PSM mRNA, particularly as a marker of the presence of metastatic prostatic cancer cells in the circulation, 11 is an even more exciting development than antibody-based methods. However, there is a need to standardise PCR assays. This will eventually allow more accurate evaluation of the results emerging from various national and international groups, and resolve a continuing debate as to the relative sensitivities and speci®cities of PSA or PSM based PCR diagnostic testing.
11±13

Molecular characterisation of PSM
The type II membrane glycoprotein PSM 14 is recognised by the monoclonal antibody (mAb) 7E 11 .C5. 15 This mAb was raised against the human prostate cancer cell line LNCaP. 16 The original intention was to raise an antibody to unique antigens on the surface of prostate cancer cells. Targeting of human tumours for diagnostic and therapeutic purposes with mAbs is an attractive approach which is based on the premise that cancer-speci®c antigens exist. Therefore, anti-PSM antibody conjugates have been subsequently evaluated for immunostaging and immunotherapy in prostate cancer patients.
Type II glycoprotein antigens are usually either proteases, membrane associated receptors or transport proteins. PSM was ®rst shown to have protease activity, which may have implications in the metastatic process. 17 Interestingly, a folate g-glutamyl hydrolase activity of PSM was later noted, 18 and this may be important as cancer cells that express this latter enzyme have previously been found to be resistant to methotrexate chemotherapy. 19 Peptide microsequencing of puri®ed protein allowed the cloning of a PSM cDNA. 20 This is 2.65 kb in length and encodes a 750 amino acid (aa) open reading frame. The protein consists of a short 19 aa cytoplasmic (N-terminal) region, a 24 aa transmembrane domain and a 707 aa extracellular C-terminal fragment. The PSM protein has a predicted molecular weight (MW) of 84 kDa but in vivo glycosylation increases this to approximately 100 kDa. In most individuals, the oligosaccharides on PSM are predominantly N-linked with 10 such potential sites. 21 Carbohydrate constitutes roughly 25% of the total molecular weight.
The epitope recognised by 7E11.C5 is located at the Nterminus of the PSM protein and is therefore thought to be intracellular. Therefore, the way in which 7E11.C5 achieves speci®city in the recognition and imaging of prostate cancer has been unclear. It has therefore been postulated that this labelled antibody binds only to dead cells and/or cellular debris in metastatic prostate tumours, as opposed to labelling viable cells. This ambiguity was investigated in the LNCaP cell line. 22 Barren et al, 22 concluded that somehow this cell line's membranes are permeable and hypothesised that this formed the basis of the mAb's apparent uptake into viable cells. Their approach involved scraping sections off slides and has been criticised because this processing may damage the cell membrane with consequent artefactual uptake of mAb. Thus, the claimed prostatic cancer selectivity of the antibody in vivo has not been convincingly explained.
Mapping of the PSM/FOLH1 gene
The PSM gene, subsequently given the systematic GDB symbol FOLH1, was mapped to either the short arm (11p11.2) or long arm (11q14) of human chromosome 11 by different investigators. 23Y 24 Fluorescent in-situ hybridisation (FISH) analysis showed dual signals on both the short and long arms, suggesting the possibility of genetic duplication of the region and therefore the potential presence of a second related gene. Additionally, evidence for the existence of related sequences in man was provided by Southern blotting. 23 Leek et al, 23 assigned FOLH1 to the 11p11.2 locus on the basis of primed in-situ (PRINS) analysis. This was in contradistinction to the ®ndings of Rinker-Schaeffer et al. 24 who detected similar dual signals with FISH. However, at higher stringency of hybridisation using a genomic DNA cosmid probe, only the 11q14 signal was visualised. They therefore suggested the long arm as being the true location of the FOLH1 gene.
On balance, the 11p11.2 region is now thought to be the more likely location of the known human FOLH1 gene as evidenced by sequencing and detailed genetic mapping studies. 25 These studies also suggest extensive genetic duplication in these two regions (11p11.2 and 11q14). This phenomenon is observed elsewhere in the human genome and usually some members of the resulting gene families eventually lose function and become pseudogenes. 26 Sequencing of the C-terminal portion of the putative FOLH1-related gene using DNA derived from 11q14 has revealed a reading frame shift such that in frame stop codons are introduced, thereby removing Cterminal amino acids from PSM. 24 This suggests that even if the 1lq gene is indeed expressed, a truncated PSM-like protein of 713 aa would be produced. Sequencing the FOLH1 promoter in an attempt to utilise it in tumourspeci®c gene therapy for prostate cancer patients has been hindered by the possible presence of two related gene sequences. However, Heston and colleagues have recently deposited the genomic sequence upstream of the FOLH1 transcription initiation site in the public databases (Genbank Accession No. AF007544). Therefore, characterisation of this promoter should now be relatively straightfoward.
Genomic structure of FOLH1
The genomic structure of the FOLH1 gene has been obtained by extensive sequencing (AF007544). The gene spans over 90 kb of DNA and contains 19 exons. The introns vary in size from 300 bp to over 7 kb, whereas of the expressed sequences, exon 1 is the largest at 379 bp and exon 12 the smallest at 64 bp.
Sequences from both FOLH1 and potentially FOLH2 have also been deposited by others under Genbank Accession Nos. U93598, U93599, AF00741I, AF007412, AF007413, AF0011896, AF016826, AF016827, AF016828, AF016829, AF016830. An alternatively spliced transcript termed FOLH1 0 (Figure 1 ), along with the previously described FOLH1, was noted in normal prostate. 27 The two transcripts differ by the presence of a 266 nucleotide region near the 5 0 end of the FOLH1 cDNA (nucleotides 114-380) that is absent in FOLH1
0 . This region includes the FOLH1 translation initiation codon and codons for the putative transmembrane domain of the protein. Exon one codes for this region and also the 5 0 UTR. Thus the FOLH1 0 splice variant would appear to encode a cytoplasmic protein utilising an alternative translation initiation site. 28 At protein level, PSM1/FOLH1 and the transferrin receptor share 46% homology. The signi®cance of this observation is largely unknown but one can speculate that there may be a common ancestral origin for both these proteins.
PSM/FOLH1 expression pro®le
Ribonuclease protection assays, immunohistochemical staining and western blotting initially showed the PSM/ FOLH1 expression pro®le to be largely prostate restricted Prostate-speci®c membrane antigen (FOLH1) BH Maraj and AF Markham with small but signi®cant levels in human salivary glands, small intestine and brain. 29 Subsequently, the immunohistological data utilising unlabelled mAb Cyt-351 was re-evaluated. 30 PSM was detected in prostatic epithelium, duodenal mucosa and a subset of proximal renal tubules. Moreover, the unexpected and striking observation of PSM/FOLH1 immunoreactivity in the endothelial cells of capillaries from tumours other than prostate cancer, raised the possibility of a role in angiogenesis and therefore the potential for targeting tumour neovasculature as well as carcinoma cells themselves with anti-PSM antibodies. 30 More recently, Liu, 31 developed a new anti-PSM monoclonal antibody to an epitope in the extracellular domain of this protein and con®rmed the observations of Silver and colleagues. 30 Targeting tumour neovasculature may be more effective than conventional anticancer therapeutic approaches as endothelial cells are known to be genetically stable compared to tumour cells and consequently less likely to develop resistance to treatments which might induce apoptosis. 32 As PSM/FOLH1 has a putative role in folate metabolism, its possible relevance in coeliac disease was considered. 33 It was shown that loss of FOLH1 expression is unlikely to contribute to the folate de®ciency which is sometimes associated with untreated coeliac disease. However, the persistent expression of FOLH1, even in the affected epithelium of untreated coeliacs, con®rms that this gene is not expressed in a prostate-speci®c manner. This raises the serious possibility of cross reactivity with the small intestine inducing potentially serious side effects such as duodenitis, in immunotherapy regimens. FOLH1 expression is upregulated after androgen deprivation therapy. By immunohistochemical analysis and western blotting on both pre-and post-androgen deprivation prostate cancer patients, as well as on the LNCaP cell line, 34 increased expression of FOLH1 after androgen depletion was noted. It was therefore suggested that use of a labelled anti-PSM mAb might be particularly appropriate in the treatment of hormone escape patients previously treated by androgen deprivation. Diamond et al. 35 investigated the effects of growth factors and noted that bFGF also increased the expression of FOLH1 by over 1000% at the mRNA level. Thus the effectiveness of the labelled mAb might again be enhanced by manipulating FOHL1 expression with this growth factor. Recently, Kawakami et al 36 investigated the expression of FOLH1 utilising a FOLH1 mRNA probe for in-situ hybridisation and found increased expression in prostate cancer correlating with increasing Gleason's grade and hormone refractory disease, which is also in agreement with the above studies.
Clinical signi®cance of PSM/FOLH1
Molecular staging of prostate cancer
The idea of examining peripheral blood for circulating cancer cells in an attempt to assess stage and consequent prognosis, ultimately as a guide to appropriate treatment, is not new. One of the earliest reports in 1869, 37 described a 38 y old male, who was admitted with a diagnosis of`r heumatism and debility' and subsequently died 24 h later. Microscopic examination of both the blood cells and those of a suspected primary cancer, revealed that both the primary and certain cells in the blood had similar characteristics. It was therefore concluded that the abnormal blood cells arose from the primary site and subsequently escaped into the circulation.
With the invention of the sensitive polymerase chain reaction (PCR), 38 it became possible to apply this technique to detect circulating cancer cells, by amplifying their mRNA. The ®rst report comparing FOLH1 and PSA expression in peripheral blood, 11 produced alarming results in that 25% of patients with prostate cancer described as having localised disease by conventional methods were found to have cells in the circulation from which these transcripts could be ampli®ed. The implication is that this re¯ects the presence of signi®cant numbers of circulating prostate cancer cells. Though important, the ®nding of cancers cells in the circulation may not necessarily imply metastatic disease, as less than 1% of such cells probably actually go on to establish secondary foci. However, there is clearly a need for precise follow up on this particular group of patients.
Several groups have now examined the PCR technique, 11±13,39 with con¯icting results as to whether FOLH1 primers have a better predictive value than those based on PSA, for application in RT-PCR for the molecular staging of prostate cancer. These studies are dif®cult to compare directly because both different PCR primers and experimental techniques were used. Recently, there have unfortunately been reports of expression of both these genes by circulating leukocytes. 40Y 41 This phenomenon, possibly a re¯ection of`illegitimate' leaky expression, complicates evaluation of the RT-PCR technique and highlights the urgent requirement for standardised methods of PCR-based diagnosis for the presence of circulating prostate cancer cells. 42 It will be essential to exclude this background expression of both FOLH1 and PSA. When optimising such reactions, it will also be important to focus on the putative FOLH1 variant when constructing RT-PCR based assays for circulating tumour cells, as it will presumably be critical to achieve discrimination from the 11q14 FOLH2 gene, should this be transcribed into mRNA.
Anti-PSM (FOLH1) monoclonal antibodies in the management of prostate cancer
Contemporary practice for detecting lymph node metastasis in prostate cancer is by histological examination after surgical exploration and excision. CT scanning-based diagnosis relies simply on lymph node size. Metastatic prostate cancer nodes are usually small and less than 1 cm. 43 Consequently, the sensitivity of CT scanning for this purpose is less than 20% which is roughly similar to MRI results. 44 It is in this context that PSM (FOLH1) might ®nd its most useful clinical application. The immunoconjugate of 7E11.C5, which is designated Cyt-356, has been the most widely analysed anti-PSM/FOLH1 mAb to date. CT scanning will only detect nodes greater than 1.5 cm, whereas 111 In labelled Cyt-356 has been shown to visualise those as small as 5 mm. 7 In that study the immunolabelled mAb was found to provide 30±40% higher sensitivity than CT scanning or MRI alone. Krynyckyi et al, 8 carried out a multicentre trial including both pre-and postoperative patients with biopsy proven prostate cancer. Overall they found that immunoscintigraphy using 111 In Cyt-356 was useful in evaluating patients with occult disease and detecting disease outside the ®eld of surgical exploration. Cyt-356, labelled with 111 In has completed a clinical trial in the assessment of suspected recurrence of prostate cancer post-radical treatment. 10 The 90 Y labelled counterpart of Cyt-356 has recently entered phase III trials in the treatment of patients with relapsed disease. Such treatment was attempted in patients with hormone refractory prostate cancer. 45 No patient attained a complete response based on serum PSA levels and/or radiological criteria. In this study, myelosuppression was found to be the dose-limiting toxicity.
90
Y Cyt-356 was evaluated in the treatment of recurrent prostate cancer after radical prostatectomy, using serum PSA and
111
In Cyt-356 scans as response endpoints. 9 Again, marrow toxicity was universal and PSA decreases only transient. EDTA, a chelating agent which removes free yttrium from the circulation has been included in more recent protocols. The complex is then excreted in the urine, resulting in reduced marrow toxicity. 46 Therefore, to date the results of anti-PSM/FOLH1 immunotherapy remain inconclusive and it is dif®cult to predict the eventual clinical value of 90 Y Cyt-356 at this stage. Antibody-directed, enzyme activated prodrug therapy (ADEPT), 47 is another potential application of the anti-PSM/FOLH1 mAbs which could deliver a targeted enzyme to activate a prodrug. This was suggested as an alternative to previous cancer targeting techniques using a single bifunctional molecule (that is an anticancer agent directly coupled to a mAb which recognised a cancerspeci®c surface antigen). The`single' approach has several drawbacks, which include: heterogeniety of expression of the antigen by cancer cells; incomplete clearance of antibodies from the circulation leading to generalised, non-speci®c toxicity; reduced penetration of targeting molecules into poorly vascularised tumours with consequent cytotoxic effects in normal tissue; and host antibody responses to the foreign protein. Preliminary studies by Bagshawe, 48 suggested that administering a pro-drug after any unbound antibody-coupled enzyme had cleared the circulation, would reduce some of these recognised problems. In their work on nude mice harbouring hCGproducing CC3 xenografts of human choriocarcinoma, Bagshawe et al 47 utilised carboxypeptidase G2 coupled to a F(ab 0 ) 2 (that recognises the beta-subunit of human chorionic gonadotrophin). The peptidase converted the pro-drug, para-N-bis (2-chloroethyl) aminobenzoyl glutamic acid to the alkylating agent, benzoic acid mustard. Control infusions were saline, methotrexate, hydroxyurea and cytosine arabinoside. After a single course of treatment, growth of the tumour, which is normally resistant to conventional agents, was signi®cantly reduced in the ADEPT group only.
In the case of anti-PSM/FOLH1 antibody, the prodrug activating enzyme, cytidine deaminase could be coupled to the mAb which might then be introduced into the patient. In this example 5-FC (5-¯urocytosine), which is a non-toxic antifungal agent, would then be given to the patient. Assuming the mAb to be speci®c for a prostate cancer antigen, 5-FC would be converted locally to the cytotoxic 5-FU (5-¯uorouracil), which would then exert its effects in the malignant tissue only. Similarily, once the FOLH1 gene promoter is fully characterised (which should be straightfoward now that the sequence of this whole region has been identi®ed), the bacterial cytidine deaminase gene could be placed downstream of a promoter known to be active in prostate carcinoma cells, in an expression cassette within a viral gene transfer vector, to allow gene therapy based approaches. This is the so called`viral-directed enzyme activated prodrug' (VDEPT) concept, again using 5-FC as the prodrug in this example. 49 
FOLH1 splice variants
As mentioned above, an alternatively spliced transcript termed FOLH1 0 , along with the previously described FOLH1 (Figure 1 ), was noted in normal prostate. 27 The existence of FOLH1 splice variants in human prostate cancer was veri®ed by RNAse protection assays as the only anti-PSM/FOLH1 mAb available in 1995, 7E11C.5, did not recognise any epitope on the FOLH1 0 cytoplasmic protein variant, rendering immunohistochemistry impossible. FOLH1 was the predominant form in LNCaP cells whereas neither FOLH1 nor FOLH1 0 were detected in PC-3 cells, a cell line in which this gene is apparently deleted. In human primary malignant prostate tissue FOLH1 mRNA was the predominant form (10 : 1, FOLH1 : FOLH1 0 ). In contrast, normal prostate expressed more FOLH1 0 mRNA than FOLH1 mRNA (1 : 10, FOLH1 : FOLH1 0 ). BPH showed roughly equal expression of both variants. 27 It was concluded that the change in expression ratios could well be the reason for the apparent prostate cancer speci®city of this surface antigen and explain its apparent utility in the monitoring of disease progression.
Murphy et al, 50 compared f-PSA and FOLH1 (using western blot analysis with the 7E11.C5 mAb) levels and con®rmed previous observations that FOLH1 is elevated in the presence of metastatic cancer or a hormone refractory malignant state. More recently, a new anti-FOLH1 mAb, 3F5.4G6, has been evaluated. 28 This recognises an epitope at the C-terminus (aa 716-723) of both FOLH1 protein variants in contrast to the N-terminal epitope recognised by 7E1l.C5. Furthermore, this antibody should not therefore cross react with any protein expressed from the putative 11q14 locus. Western blot analyses with both mAbs on LNCaP cell line lysates recognised an identical protein (FOLH1) plus an additional product corresponding to FOLH1 0 which was only detected by 3F5.4G6. This is the ®rst direct evidence for the expression of FOLH1 0 at the protein level. This new mAb has a similar recognition pattern to 7E1I .C5 in that it reacts with FOLH1 found in the LNCaP cell line, but not with PC3 nor DU-145 derived proteins, both of which are known not to express FOLH1.
More recently, a previously unreported splice variant of FOLH1 was sequenced and termed FOLH1 00 (Figure 2 ), (Genbanic Accession No. AF027824). FOL H1 00 lacks the entire exon 18, which codes for aa 657-688. Interestingly, FOLH1 00 was sequenced from colonic cancer derived mRNA and further analysis con®rmed that the transmembrane domain (lost in FOLH1') may actually be incorporated into this product. FOLH1 00 therefore exists as two separate isoforms, with and without the transmembrane domain (Maraj et al, unpublished) . Bzdega et al, 51 also reported this splice variant in the rat, which they noted in normal brain, prostate and liver. That represented the ®rst description of FOLH1 transcripts in the liver.
Conclusions
Physical mapping of the FOLH1 gene and a putative related gene(s) has been problematic and somewhat controversial. However, this has now been resolved. 25, 52 Detailed genetic analysis has allowed localisation of the FOLH1 gene to the 1lp11.2 chromosomal region at 62.5 cM, with a related FOLH2 gene at 11q14. Interestingly there appears to be extensive genetic duplication, over at least 500 kb, in these two regions. 25 Complete analysis of the molecular genetics of the FOLH1 gene(s) is essential to facilitate ongoing clinical evaluations. The utilisation of 111 In labelled anti-PSM/FOLH1 antibody to assess the extent of disease has shown very promising initial results when compared to other prostate cancer`speci®c' antibodies. Both PSA and PAP antibodies were previously utilised similarly but suffered major problems due to a high frequency of human anti-mouse antibodies (HAMA) and associated toxic side effects. 43 Additionally, the use of 90 Y labelled anti-FOLH1 antibody has raised some concerns due to the fact that low but signi®cant levels of FOLH1 expression have been noted in extra-prostatic tissues.
It is critical that more accurate staging methods are developed for cancer of the prostate, as contemporary methods signi®cantly understage men with a recent diagnosis of this disease. 11 These patients are then subjected, inappropriately, to major procedures with their attendant morbidity and mortality, with the intention to cure. The detection of mRNA and thus circulating cancer cells by newer techniques such as RT-PCR appears to be promising. However, it is essential to standardise these assays internationally, especially as expression of both FOLH1 and PSA has been consistently detected in circulating cells other than those arising from prostate cancers. When optimising such reactions, it will also be important to focus on the putative 11q14 FOLH2 variant as it may become critical to achieve discrimination from the FOLH2 gene, should this be transcribed into mRNA.
The most exciting feature of FOLH1 was that it did initially appear to be a genuinely tumour selective marker. Unfortunately, several reports have now suggested otherwise, in that expression of FOLH1 has also been noted in tissues outside the malignant prostate. Therefore, the`hunt' continues for the ideal prostate cancer-speci®c gene product to act as a disease-speci®c marker.
